Diagnostic Challenges

The dimension of the problem is compellingly illustrated by current study data. A comprehensive literature analysis of 23 studies on ATTR cardiomyopathy reveals alarming figures: weighted mean diagnostic delays of 6.1 years (median 3.4 years) for ATTRwt and 5.7 years (median 2.6 years) for hereditary ATTRv. These intervals represent years of suffering, disease progression, and missed treatment opportunities. Even more alarming: approximately one-third of patients initially receive an incorrect diagnosis, leading to inadequate treatment and further delay.

A central reason for diagnostic difficulty is the overlap of amyloidosis symptoms with other diseases. Cardiac amyloidosis typically presents as heart failure with preserved ejection fraction (HFpEF) — an extremely common syndrome in elderly patients. Differentiating amyloidosis-related HFpEF from conventional HFpEF is clinically challenging and requires targeted diagnostic workup. Documented misdiagnoses include Type 2 diabetes, congestive heart failure, and chronic inflammatory demyelinating polyneuropathy when neurological manifestations predominate.

The systemic nature of amyloidosis creates a further diagnostic dilemma: patients often present to different specialists with seemingly unrelated symptoms. A patient may simultaneously consult a cardiologist for heart failure, a neurologist for polyneuropathy, an orthopedist for carpal tunnel syndrome, and a gastroenterologist for GI complaints. This fragmentation of medical care frequently prevents recognition of the systemic character of the disease. Each specialist treats the manifestations within their field without recognizing the overall context.

A leading problem in amyloidosis recognition is inadequate awareness among both general practitioners and specialists. Historically, amyloidosis was regarded as a rare, incurable disease, leading to therapeutic nihilism — many physicians did not include it in their differential diagnosis. Low disease awareness is compounded by the lack of structured educational programs. Many physicians have had limited exposure to amyloidosis patients during training and are unfamiliar with the subtle clinical signs.

Traditionally, cardiac amyloidosis diagnosis required endomyocardial biopsy with histopathological examination — an invasive procedure with inherent risks. This deterred many clinicians and delayed diagnostic workup. Availability was often restricted to specialized centers. The requirement for specialist expertise in Congo red staining interpretation and amyloid typing presented further hurdles. Today, non-invasive diagnostic algorithms — particularly nuclear imaging with ⁹⁹mTc-DPD scintigraphy — have revolutionized the diagnostic paradigm.

Despite identification of characteristic 'red flags,' these diagnostic clues are underutilized in clinical practice. Red flags are typical cardiac and extracardiac manifestations that can precede the definitive diagnosis by years and should play a decisive role in early detection:

Cardiac Red Flags:

Extracardiac Red Flags:

The clinical consequences of diagnostic delay are severe and well-documented. A delay of more than three months in ATTRwt cardiomyopathy is associated with significantly higher NYHA classification at diagnosis — indicating more advanced disease. Studies show that delay of more than one year correlates with higher NT-proBNP levels, prolonged PR intervals, and higher prevalence of intraventricular conduction disorders and atrial fibrillation.

MYCOR's SYGNAL algorithm transforms amyloidosis detection from an incidental finding into a systematic process. By analyzing standard 12-lead ECGs using weighted analysis of ECG-derived parameters, SYGNAL identifies subtle biophysical signal patterns — including QRS voltage discrepancies and specific biomarker constellations — that precede clinical diagnosis by years. Non-invasive, cloud-based, and deployable at scale, SYGNAL addresses precisely the diagnostic gap that current clinical pathways leave open.